Catalysts / FTH
Upcoming FDA decisions and readouts we track for Faeth Therapeutics, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Faeth Therapeutics (FTH, listed on Nasdaq). They cover 2 programmes: PIK-201 (PIKTOR) (Endometrial cancer) and PIK-101 (PIKTOR) (HR-positive breast cancer).
First on the list: the Phase 2 readout for PIK-201 (PIKTOR) (Endometrial cancer), guided by the company to Late 2026. By stage, the upcoming rows are 1 Phase 1B/2 readout and 1 Phase 2 readout.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Faeth Therapeutics FTH · Nasdaq | PIK-201 (PIKTOR) | Endometrial cancer | Late 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Faeth Therapeutics FTH · Nasdaq | PIK-101 (PIKTOR) | HR-positive breast cancer | 2027 company guidance |
Phase 1B/2 readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList